Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain

Acta Psychiatrica Scandinavica

Volumn 114, Issue SUPPL. 432, 2006, Pages 29-38

  Gutierrez Recacha, P ^a   Chisholm, D ^b   Haro, J M ^c   Salvador Carulla, L ^d   Ayuso Mateos, J L ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c PARC SANITARI SANT JOAN DE DÉU   (Spain)

^d UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

Cost of illness; Cost benefit analysis; Epidemiology; Schizophrenia; Spain

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SPAIN;

EID: 33750698960     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00917.x     Document Type: Article

References (41)

1. JABLENSKY A, SARTORIUS N, ERNBERG G et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992;20:1-97.
2. World Health Organization. The World Health Report 2001 - mental health: new understanding, new hope. Geneva: World Health Organization, 2001.
3. USTUN TB, REHM J, CHATTERJI S et al. Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group. Lancet 1999;354:111-115.
4. GROVER S, AVASTHI A, CHAKRABARTI S, BHANSALI A, KULHARA P. Cost of care of schizophrenia: a study of Indian outpatient attenders. Acta Psychiatr Scand 2005;112:54-63.
5. HARO JM, EDGELL ET, JONES PB et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-232.
6. HARO JM, EDGELL ET, NOVICK D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-231.
7. LAMBERT M, HARO JM, NOVICK D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-243.
8. BURNS T, CHRISTOVA L, COOPER S et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006;113:126-134.
9. KNAPP M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand Suppl 2000;407:15-18.
10. PALMER CS, BRUNNER E, RUIZ-FLORES LG, PAEZ-AGRAZ F, REVICKI DA. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res 2002;33:572-580.
11. ANDREWS G, SANDERSON K, CORRY J, ISSAKIDIS C, LAPSLEY H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 2003;183:427-435.
12. BASU A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res 2004;71:445-462.
13. MAGNUS A, CARR V, MIHALOPOULOS C, CARTER R, VOS T. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 2005;39:44-54.
14. USTUN TB, AYUSO-MATEOS JL, CHATTERJI S, MATHERS C, MURRAY CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
15. MURRAY CJ, LOPEZ AD. Quantifying disability: data, methods and results. Bull World Health Organ 1994;72:481-494.
16. MURRAY CJ, LOPEZ AD, JAMISON DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994;72:495-509.
17. TAN TORRES T, BALTUSSEN RM, ADAM T et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
18. AYUSO-MATEOS JL, GUTIERREZ-RECACHA P, HARO JM, CHISHOLM D. Estimating the prevalence of schizophrenia in Spain using a disease model. Schizophr Res 2006;86:194-201.
19. VAZQUEZ-BARQUERO JL, CUESTA NUNEZ MJ, DE LAVARGA M, HERRERA CASTANEDO S, GAITE L, ARENAL A. The Cantabria first episode schizophrenia study: a summary of general findings. Acta Psychiatr Scand 1995;91:156-162.
20. IGLESIAS GARCÍA C. la incidencia administrativa de esquizofrenia en Asturias. Ann Psiquiatr 2001;17:87-93.
21. MATA I, BEPERET M, MADOZ V, Grupo PSICOST. Prevalencia e incidencia de la esquizofrenia en Navarra. An Sist Sanit Navar Suppl 2000;23(suppl. 1):29-36.
22. BARENDREGT JJ, VAN OORTMARSSEN GJ, VOS T, MURRAY CJ. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr 2003;1:4.
23. MORENO-KÜSTNER B. Prevalencia tratada en la esquizofrenia tratada en la esquizofrenia y trastornos afines. In: Moreno Küstner B, ed. El registro de casos de esquizofrenia de Granada. Madrid: Asociación Española de Neuropsiquiatría, 2005.
24. HARRIS EC, BARRACLOUGH B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
25. ANDREWS G, SANDERSON K, CORRY J, LAPSLEY HM. Using epidemiological data to model efficiency in reducing the burden of depression*. J Ment Health Policy Econ 2000;3:175-186.
26. LEUCHT S, PITSCHEL-WALZ G, ABRAHAM D, KISSLING W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
27. MOJTABAI R, NICHOLSON RA, CARPENTER BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull 1998;24:569-587.
28. MARSHALL M, GRAY A, LOCKWOOD A, GREEN R. Case management for people with severe mental disorders. Cochrane Database Syst Rev 2000;CD000050.
29. MARSHALL M, LOCKWOOD A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000;CD001089.
30. ADAM T, EVANS DB, MURRAY CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003;1:3.
31. SALVADOR-CARULLA L, HARO JM, CABASES J, MADOZ V, SACRISTAN JA, VAZQUEZ-BARQUERO JL. Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in north-east Spain. PSICOST Group. Acta Psychiatr Scand 1999;100:335-343.
32. SALDIVIA BS, TORRES GF, CABASES HITA JM. Estimation of mental health care cost units for patients with schizophrenia. Actas Esp Psiquiatr 2005;33:280-285.
33. VAZQUEZ-POLO FJ, NEGRIN M, CABASES JM, SANCHEZ E, HARO JM, SALVADOR-CARULLA L. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005;8:153-165.
34. HARO JM, SALVADOR-CARULLA L, CABASES J, MADOZ V, VAZQUEZ-BARQUERO JL. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 1998;173:334-340.
35. ANDREWS G, ISSAKIDIS C, SANDERSON K, CORRY J, LAPSLEY H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br J Psychiatry 2004;184:526-533.
36. SACRISTAN JA, GOMEZ JC, SALVADOR-CARULLA L. Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia + + in Spain. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997;25:225-234.
37. HUNTER RH, JOY CB, KENNEDY E, GILBODY SM, SONG F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2003;CD000440.
38. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization, 2001.
39. VOS T, HABY MM, MAGNUS A, MIHALOPOULOS C, ANDREWS G, Carter R. Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 2005;39:701-712.
40. CHISHOLM D, VAN OMMEREN M, AYUSO-MATEOS JL, SAXENA S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005;187:559-567.
41. CHISHOLM D, SANDERSON K, AYUSO-MATEOS JL, SAXENA S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004;184:393-403.